HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study. (Q34133528)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164415%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

review article

1 reference

title

HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164415%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

1 reference

coronary artery disease

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164415%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

author name string

J P Després

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164415%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

I Lemieux

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164415%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

G R Dagenais

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164415%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

B Cantin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164415%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 December 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164415%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164415%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

153

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164415%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164415%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

263-272

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164415%20AND%20SRC:MED&resulttype=core&format=json

Epidemiology of coronary heart disease: the Framingham study.

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Beyond LDL cholesterol reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Epidemiology of triglycerides: a view from Framingham

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Hypertriglyceridemia and its metabolic consequences as a risk factor for atherosclerotic cardiovascular disease in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Triglycerides: a risk factor for coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Hypertriglyceridemia: risks and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Hypertriglyceridemia and regulation of fibrinolytic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Atherothrombogenicity of lipoprotein(a): the debate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Banting lecture 1988. Role of insulin resistance in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Plasma homocysteine levels and mortality in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Essential hypertension: renin and aldosterone, heart attack and stroke.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Atherosclerosis — An Inflammatory Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Novel inflammatory markers of coronary risk: theory versus practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Triglyceride as a risk factor for coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Small LDL, atherogenic dyslipidemia, and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Did grandma give you heart disease? The new battle against coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

New lipoprotein profiles and coronary heart disease. Improving precision of risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Postprandial triglyceride response in visceral obesity in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Hyperglycemia and cardiovascular disease in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

HDLs and alimentary lipemia. Studies in men with previous myocardial infarction at a young age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Triglyceride-rich lipoproteins and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

Plasma triglyceride and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900603-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0021-9150(00)00603-1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164415%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference